Key Takeaways
- Doctors’ high earnings and assets make them attractive targets for scammers.
PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors
Understanding the Unique Vulnerabilities That Make Physicians Prime Targets for Sophisticated Financial Fraud Schemes
Listen to this article
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Learn what's happening at the US FDA. On the go.
More from Market Access
The Centers for Medicare and Medicaid Services is considering imposing price inflation rebates on Part B drugs furnished to enrollees in Medicare Advantage plans in addition to those covered by fee-for-service Medicare.
• By
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
• By
Hemgenix has now secured reimbursement in several European markets, and while the path to reimbursement for the high-cost product has not always been easy, innovative access deals have helped to smooth the way.
• By
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
More from Pricing Debate
• By
Industry says it is ready to work with the government on the recommendations from a major review of Australia’s health technology assessment system that covers areas such as discount rate reductions and setting up a separate budgetary allocation to temporarily subsidize access to certain drugs.
• By
CBER Director Peter Marks said recent leaps in gene therapy science have not been matched by more affordable manufacturing technology and that there is a need to set a cost-effectiveness target for the field.
• By
US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.